Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Ebola outbreak: 4th case confirmed in Mbandaka - Outbreak News Today - Outbreak News Today
  Sat, 21 May 2022 17:46 GMT
• Ebola virus disease - Democratic Republic of the Congo - World Health Organization
  Thu, 28 Apr 2022 07:00 GMT
• Ebola outbreak in DR Congo - The Lancet
  Sat, 07 May 2022 07:00 GMT
• DR Congo: Ebola Outbreak - Apr 2022 - ReliefWeb
  Thu, 28 Apr 2022 18:25 GMT
• WHO concerned over resurgence of Ebola — MercoPress - MercoPress
  Mon, 02 May 2022 21:35 GMT
• Ebola symptoms: 11 key symptoms of Ebola virus disease - what to do if you have them - Express
  Wed, 27 Apr 2022 07:00 GMT
• Ugandan preparedness and response to 2018-2020 Ebola outbreaks highlights path for other nations - Homeland Preparedness News
  Tue, 17 May 2022 13:18 GMT
• Monkeypox: Time to worry or one to ignore? - BBC
  Fri, 20 May 2022 23:24 GMT
• Report: Russian lawmaker claims US researched Ebola and smallpox viruses in Ukraine - The Edge Markets MY
  Sat, 21 May 2022 05:44 GMT
• Lassa fever - Guinea - World Health Organization
  Fri, 13 May 2022 17:27 GMT
• Ebola virus hides out in brain - ASBMB Today
  Sun, 17 Apr 2022 04:56 GMT
• DRC: Media statement on the end of the 13th Ebola outbreak - International Federation of Red Cross and Red Crescent Societies
  Thu, 16 Dec 2021 08:00 GMT
• The Ebola virus can 'hide out' in the brain after treatment and cause recurrent infections - The Conversation Indonesia
  Tue, 15 Mar 2022 07:00 GMT
• Lara Logan, Once a Star at CBS News, Is Now One for the Far Right - The New York Times
  Sun, 22 May 2022 09:00 GMT
• Study reveals Ebola virus can hide in brain, persist even years after treatment - Science Daily
  Wed, 09 Feb 2022 08:00 GMT

• PRO/AH/EDR> Ebola update (44): Burkina Faso ex Cote d'Ivoire, 2nd case, NOT
  Mon, 30 Aug 2021 11:01:25 -0400
  Ebola -- Burkina Faso
  On 22 Aug 2021, the Ministry of Health informed the population of the admission to the Medical Emergencies of the Bogodogo University Hospital (CHU-B) of a 22-year-old patient who had stayed in the Republic of [Cote d'Ivoire]. The diagnostic procedure consisted of sampling analysis at the National Reference Laboratory for Viral Haemorrhagic Fever (LNR-FHV at the Muraz Centre) and the Pasteur Institute of Dakar for confirmation. The results obtained make it possible to permanently rule out

• Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus Fri, 20 May 2022 06:00:00 -0400
  Immunoglobulin gene heterogeneity reflects the diversity and focus of the humoral immune response towards different infections, enabling inference of B cell development processes. Detailed compositional and lineage analysis of long read IGH repertoire sequencing, combining examples of pandemic, epidemic and endemic viral infections with control and vaccination samples, demonstrates general responses including increased use of IGHV4-39 in both Zaire Ebolavirus (EBOV) and COVID-19 patient cohorts....
• Implementing a DHIS2 Ebola virus disease module during the 2021 Guinea Ebola outbreak Thu, 19 May 2022 06:00:00 -0400
  In 2017, the national agency for health security (L'Agence Nationale de Sécurité Sanitaire-ANSS) in Guinea implemented the District Health Information Software (DHIS2) as the Ministry of Health national surveillance system to capture and report aggregate disease data. During 2019, the ANSS started using DHIS2 Tracker to collect case-based (individual-level) data for epidemic-prone diseases. In 2020, the capability was expanded, and it was used during the COVID-19 pandemic to capture data...
• Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study Thu, 19 May 2022 06:00:00 -0400
  BACKGROUND: Whether or not individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease develop clinical sequelae is unknown. We assessed current symptoms and physical examination findings among individuals with pauci-symptomatic or asymptomatic infection and unrecognised Ebola virus disease compared with Ebola virus disease survivors and uninfected contacts.
• Special Pathogens Readiness in the United States: from Ebola to COVID-19 to Disease X and Beyond Thu, 19 May 2022 06:00:00 -0400
  No abstract
• Beyond Lassa Fever: Systemic and structural barriers to disease detection and response in Sierra Leone Thu, 19 May 2022 06:00:00 -0400
  CONCLUSIONS/SIGNIFICANCE: Identification of ways to improve the system requires balancing vertical disease surveillance programmes against other population health needs. Therefore, health system challenges to early identification of LF specifically have implications for the effectiveness of the wider Integrated Disease Surveillance and Response (IDSR) system in Sierra Leone more generally. Sentinel surveillance or improved surveillance at maternity facilities would help improve viral...
• The Evolution of the National Special Pathogen System of Care Thu, 19 May 2022 06:00:00 -0400
  Infectious disease outbreaks and pandemics have repeatedly threatened public health and have severely strained healthcare delivery systems throughout the past century. Pathogens causing respiratory illness, such as influenza viruses and coronaviruses, as well as the highly communicable viral hemorrhagic fevers, pose a large threat to the healthcare delivery system in the United States and worldwide. Through the Hospital Preparedness Program, within the US Department of Health and Human Services...
• COVID-19 Response Among US Hospitals with Emerging Special Pathogen Programs Wed, 18 May 2022 06:00:00 -0400
  In February 2015, the US Department of Health and Human Services developed a tiered hospital network to deliver safe and effective care to patients with Ebola virus disease (EVD) and other special pathogens. The tiered network consisted of regional special pathogen treatment centers, state- or jurisdiction-designated treatment centers, assessment hospitals able to safely isolate a patient until a diagnosis of EVD was confirmed and transfer the patient, and frontline healthcare facilities able to...
• Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region Wed, 18 May 2022 06:00:00 -0400
  The three human pathogenic ebolaviruses: Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, cause severe disease with high fatality rates. Epitopes of ebolavirus glycoprotein (GP) recognized by antibodies with binding breadth for all three ebolaviruses are of major interest for rational vaccine design. In particular, the heptad repeat 2 -membrane-proximal external region (HR2-MPER) epitope is relatively conserved between EBOV, BDBV, and SUDV GP and targeted by human broadly-neutralizing...
• Correction: Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo Wed, 18 May 2022 06:00:00 -0400
  [This corrects the article DOI: 10.1371/journal.pntd.0009566.].
• Mental disorders following COVID-19 and other epidemics: a systematic review and meta-analysis Tue, 17 May 2022 06:00:00 -0400
  COVID-19 has imposed a very substantial direct threat to the physical health of those infected, although the corollary impact on mental health may be even more burdensome. Here we focus on assessing the mental health impact of COVID-19 and of other epidemics in the community. We searched five electronic databases until December 9, 2020, for all peer-reviewed original studies reporting any prevalence or correlates of mental disorders in the general population following novel epidemics in English,...